Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases... Show more
The 10-day moving average for CELU crossed bullishly above the 50-day moving average on April 24, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CELU just turned positive on May 02, 2025. Looking at past instances where CELU's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .
CELU moved above its 50-day moving average on May 01, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CELU advanced for three days, in of 236 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 137 cases where CELU Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Momentum Indicator moved below the 0 level on May 08, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CELU as a result. In of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CELU declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.328) is normal, around the industry mean (14.243). P/E Ratio (0.000) is within average values for comparable stocks, (62.770). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.866). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (0.178) is also within normal values, averaging (253.449).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CELU’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CELU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
a blank check company, which focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization
Industry Biotechnology
A.I.dvisor tells us that CELU and NVCT have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CELU and NVCT's prices will move in lockstep.
Ticker / NAME | Correlation To CELU | 1D Price Change % | ||
---|---|---|---|---|
CELU | 100% | -0.60% | ||
NVCT - CELU | 28% Poorly correlated | +5.25% | ||
FATE - CELU | 27% Poorly correlated | +3.00% | ||
PRAX - CELU | 27% Poorly correlated | -0.08% | ||
CYBN - CELU | 26% Poorly correlated | +6.76% | ||
RNAC - CELU | 26% Poorly correlated | +2.66% | ||
More |